Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BMRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$261.00+0.5%$242.89$160.86▼$282.15$16.21B0.37840,958 shs668,250 shsBMRNBioMarin Pharmaceutical$59.59-0.7%$55.92$49.26▼$66.28$11.60B0.241.61 million shs1.61 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.46%-3.49%+12.91%+6.76%+48.80%BMRNBioMarin Pharmaceutical-0.68%+0.79%+8.31%+9.06%+2.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$261.00+0.5%$242.89$160.86▼$282.15$16.21B0.37840,958 shs668,250 shsBMRNBioMarin Pharmaceutical$59.59-0.7%$55.92$49.26▼$66.28$11.60B0.241.61 million shs1.61 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.46%-3.49%+12.91%+6.76%+48.80%BMRNBioMarin Pharmaceutical-0.68%+0.79%+8.31%+9.06%+2.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.05Buy$295.6713.28% UpsideBMRNBioMarin Pharmaceutical 2.71Moderate Buy$88.2648.11% UpsideCurrent Analyst Ratings BreakdownLatest ASND and BMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026BMRNBioMarin Pharmaceutical CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $76.007/15/2026ASNDAscendis Pharma A/S Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C)7/14/2026BMRNBioMarin Pharmaceutical UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral7/14/2026BMRNBioMarin Pharmaceutical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral7/7/2026ASNDAscendis Pharma A/S Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$275.00 ➝ $280.007/7/2026BMRNBioMarin Pharmaceutical Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$66.00 ➝ $62.006/26/2026BMRNBioMarin Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)6/22/2026BMRNBioMarin Pharmaceutical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral6/11/2026BMRNBioMarin Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/9/2026ASNDAscendis Pharma A/S OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/29/2026BMRNBioMarin Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$865.78M18.80N/AN/A($2.97) per share-87.88BMRNBioMarin Pharmaceutical$3.22B3.58$2.83 per share21.03$31.68 per share1.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6730.1021.50N/A57.87%N/A-8.37%8/6/2026 (Estimated)BMRNBioMarin Pharmaceutical$348.90M$1.3743.5010.660.468.29%6.50%5.07%8/3/2026 (Estimated)Latest ASND and BMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026ASNDAscendis Pharma A/S$1.27N/AN/AN/A$438.69 millionN/A8/3/2026Q2 2026BMRNBioMarin Pharmaceutical$0.96N/AN/AN/A$939.23 millionN/A5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72BMRNBioMarin Pharmaceutical0.235.814.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABMRNBioMarin Pharmaceutical98.71%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BMRNBioMarin Pharmaceutical0.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBMRNBioMarin Pharmaceutical3,221193.28 million191.64 millionOptionableASND and BMRN HeadlinesRecent News About These CompaniesIllinois Municipal Retirement Fund Has $7.51 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN3 hours ago | marketbeat.comCitigroup Forecasts Strong Price Appreciation for BioMarin Pharmaceutical (NASDAQ:BMRN) StockJuly 18 at 2:50 AM | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 18 at 2:14 AM | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 18 at 2:13 AM | marketbeat.com2 reasons to avoid BMRN and 1 stock to buy insteadJuly 17 at 1:59 PM | msn.comBioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $76.00 at CitigroupJuly 16 at 4:35 PM | marketbeat.comFDA Accepts BMRN's sNDA Seeking Full Approval for VoxzogoJuly 14, 2026 | zacks.comBioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For UndervaluationJuly 13, 2026 | finance.yahoo.comBioMarin (BMRN) Holds Steady Near Support as Biotech Sector Faces Headwinds - PCR Moving AverageJuly 13, 2026 | donanimhaber.comDBioMarin (BMRN) Holds Steady Near Support as Biotech Sector Faces Headwinds - FRAMA SignalJuly 13, 2026 | donanimhaber.comDU.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With AchondroplasiaJuly 13, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), BioMarin Pharmaceutical (BMRN) and Precision BioSciences (DTIL)July 11, 2026 | theglobeandmail.comTorray Investment Partners LLC Buys Shares of 78,170 BioMarin Pharmaceutical Inc. $BMRNJuly 11, 2026 | marketbeat.comBioMarin’s Gene Therapy Study in Tough Hemophilia A Patients Reaches Completion: What Investors Should WatchJuly 10, 2026 | tipranks.comJefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)July 10, 2026 | theglobeandmail.comHere's Why BioMarin Pharmaceutical (BMRN) is a Strong Value StockJuly 1, 2026 | zacks.comTherapeutics stocks Q1 teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) vs the restJune 25, 2026 | msn.comBioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia TreatmentJune 23, 2026 | finance.yahoo.comBioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026June 16, 2026 | prnewswire.comBioMarin Pharmaceutical (BMRN) Receives a Buy from GuggenheimJune 10, 2026 | theglobeandmail.comBiomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 YearsJune 8, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASND and BMRN Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$261.00 +1.20 (+0.46%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$261.11 +0.11 (+0.04%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BioMarin Pharmaceutical NASDAQ:BMRN$59.59 -0.41 (-0.68%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$58.50 -1.09 (-1.83%) As of 07/17/2026 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
